In a single-center study, 32 subjects with knee osteoarthritis were randomized to receive either intravenous VOLT01 or zoledronic acid.
The study found that that VOLT01 significantly reduced pain as compared to ZA when measured by the change in mean Visual Analogue Scale and significantly decreased the incidence of post-dose syndrome as compared to ZA. Only 12.5 percent of patients receiving VOLT01 had PDS as compared to 56.3 percent of those who received ZA.
A current phase III multi-center clinical trial with in Australia will assess VOLT01 for controlling knee osteoarthritis with results expected in 2015.
More articles on orthopedics:
Dr. Patricia McDougall Schick joins Prevea Regional Orthopedic Center
AAOS census: 5 most common orthopedist specialty areas
American Society for Surgery of the Hand honors Dr. Mark Vitale
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
